Enanta Pharmaceuticals | Операционный Доход





Операционный доход Изменить Дата
AbbVie USD 5.81B 1.23B 2025-12
Amgen USD 3.96B 464M 2025-12
Anika Therapeutics USD -4.28M 32.1M 2025-03
Arrowhead Research USD 40.81M 3.3M 2025-12
AstraZeneca USD 2.97B 4.48B 2025-12
BioCryst Pharmaceuticals USD -2.54M 10.23M 2024-12
Biogen USD 659.6M 192.2M 2025-09
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
Gilead Sciences USD 2.96B 551M 2025-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
Heron Therapeutics USD -5.66M 782K 2024-09
Immunic USD -25.73M 2.91M 2024-09
Incyte USD 383.88M 47.43M 2025-12
Insmed USD -249.71M 11.64M 2025-12
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
J&J USD 5.59B 1.81B 2025-12
Karyopharm Therapeutics USD -31.28M 5M 2024-12
Ligand Pharmaceuticals USD 158.89M 149.17M 2025-09
Merck USD 6.24B 318M 2025-12
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Novartis USD 4.5B 363M 2025-09
Novavax USD -134.02M 296.12M 2024-09
Pfizer USD 4.65B 3.99B 2025-12
PTC Therapeutics USD -81.62M 85.11M 2025-12
Roche Holding CHF 9.56B 3.8B 2025-12
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
Vertex Pharmaceuticals USD 1.26B 24.5M 2025-12


Enanta Pharmaceuticals Операционный Доход - Текущие значения, предыдущие значения, прогнозы, графики и экономический календарь - Mar 2026.